Abstract
Recently, numerous long non‑coding (lnc)RNAs have been revealed as serving important roles in human gene regulation. Previous studies have suggested that aberrant expression of lncRNAs is associated with cancer progression and metastasis. Previous studies have also demonstrated that decreased expression of WW domain‑containing oxidoreductase (WWOX) is associated with poor prognosis in numerous cancer types. However, the effect of WWOX antisense RNA 1 (WWOX‑AS1) in the development of cancer remains unknown. The aim of the present study was to investigate the role of WWOX‑AS1 in osteosarcoma. The expression levels of WWOX‑AS1 in human osteosarcoma cell lines and a normal osteoblastic cell line were investigated using reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR). The results revealed that WWOX‑AS1 expression was downregulated in osteosarcoma tissues. Furthermore, the association between WWOX‑AS1 and the prognosis of patients with osteosarcoma was investigated using Kaplan‑Meier and log‑rank tests. The results suggested that patients exhibiting high WWOX‑AS1 expression demonstrated a greater overall survival compared with patients exhibiting low WWOX‑AS1 expression. In addition, overexpression and knockdown of WWOX‑AS1 was performed using transfection experiments and confirmed by RT‑qPCR in MG63 and SAOS2 cells, respectively. The results demonstrated that WWOX‑AS1 and WWOX expression were positively correlated. Furthermore, the results of the knockdown and overexpression functional experiments suggested that WWOX‑AS1 overexpression inhibited the proliferation, migration and invasion of MG63 cells, and knockdown of WWOX‑AS1 enhanced the proliferation, migration and invasion of MG63 cells in SAOS2 cells. In conclusion, the results of the present study suggested that WWOX‑AS1 may represent a potential biomarker and therapeutic target for the treatment of osteosarcoma.